Synaptogenix is one of few companies
developing therapeutics for advanced Alzheimer's disease
(AD); no such drug has received FDA approval to date
Topline data from NIH-supported Phase 2
clinical trial for advanced AD patients expected in
current quarter
NEW
YORK, Oct. 19, 2022 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the
"Company"), an emerging biopharmaceutical company developing
regenerative therapeutics for neurodegenerative disorders, today
announced that President and Chief Scientific Officer Daniel L. Alkon, M.D. will deliver a
presentation and host meetings with investors at the upcoming
ThinkEquity Conference.
At the conference, Dr. Alkon plans to discuss the Company's
National Institutes of Health (NIH)-sponsored Phase 2 clinical
trial of its lead therapeutic candidate Bryostatin-1 for the
treatment of moderate to moderately severe AD. The trial is on
schedule for topline data during the fourth quarter of 2022.
ThinkEquity
Conference
|
|
|
|
Date:
|
October 26,
2022
|
|
|
Location:
|
The Mandarin Oriental
Hotel in New York, New York
|
|
|
Time:
|
12:00pm ET
|
|
|
Webcast
Link:
|
https://wsw.com/webcast/tep23/snpx/1709374
|
|
|
Webcast
replay:
|
Available for the
following 90 days on the Events page of the Company's Investors
website.
|
|
|
One-on-one
Meetings:
|
Investors may request
meetings online upon registration.
|
"Our priority is to develop a drug to cause real and sustained
improvement in Alzheimer's patients, a drug that will treat the
underlying disease and prevent its progression," said Dr. Alkon.
"We are pursuing our innovative AD treatment with a strategy that
has been validated in extensive preclinical models to regenerate
and regrow the synaptic connections in the brain and prevent the
death of neurons that communicate through these connections. Now is
one of the most exciting times in our Company history as we await
topline data from our Phase 2 trial."
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies for
neurodegenerative diseases. Synaptogenix has conducted clinical and
preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated Bryostatin's regenerative mechanisms of action for the
rare disease, Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its
website: www.synaptogen.com .
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 clinical trial of Bryostatin-1 and further
studies, and continued development of use of Bryostatin-1 for AD
and other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy, that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand its business, significant
government regulation of pharmaceuticals and the healthcare
industry, lack of product diversification, availability of the
Company's raw materials, existing or increased competition, stock
volatility and illiquidity, and the Company's failure to implement
its business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission. The Company does not
undertake to update these forward-looking statements.
Contact:
800-811-5591
ir@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-to-present-at-thinkequity-investor-conference-on-october-26-2022-301653267.html
SOURCE Synaptogenix, Inc.